Handbook of Therapeutic Biomarkers in Cancer

Sherry X. Yang, Janet E. Dancey

Overview: Therapeutic Biomarkers in Cancer. Statistical Considerations in the Development and Evaluation of Therapeutic Biomarkers in Cancer. Role of Biomarkers in Clinical Development of New Cancer Therapies. HER2 as a Prognostic and Predictive Biomarker in Cancer. Hormone Receptors and Endocrine Therapy in Breast Cancer. Predictive Biomarkers for Epidermal Growth Factor Receptor (EGFR) Agents in Non-Small Cell Lung Cancer. Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer. Targeting BCR-ABL for Molecular Therapy of Chronic Myelogenous Leukemia. Gastrointestinal Stromal Tumors (GISTs): From Molecular Pathogenesis to Therapy. PML/RARa Fusion Gene and Response to Retinoic Acid and Arsenic Trioxide Treatment. Dihydropyrimidine Dehydrogenase Deficiency and 5-Fluouracil Toxicity. UGT1A1 Polymorphisms and Mutations Lead to Irinotecan-Induced Toxicity. The 21-Gene Recurrence Score and Benefit of Chemotherapy in Estrogen Receptor-Positive Breast Cancer. MammaPrint for Individualized Recurrence Risk Assessment and Treatment Recommendations for Early-Stage Breast Cancer Patients. BRCA mutation and PARP Inhibitors. EML4-ALK Fusion Gene and Therapy with ALK-targeted Agents in Non-Small Cell Lung Cancer. BRAF-Targeted Therapy in Metastatic Melanoma.